Cleared Traditional

K801669 - J.T. BAKER ALPHA-1-ANTITRYPSIN NEPHELO

K801669 is the FDA 510(k) clearance for J.T. BAKER ALPHA-1-ANTITRYPSIN NEPHELO by J.T. Baker Chemical Co.. It is a Class 2 Immunology device (product code DEM) cleared through the Traditional 510(k) pathway after a 56-day FDA review.

K801669 · J.T. Baker Chemical Co. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1980
Decision
56d
Days
Class 2
Risk

K801669 is an FDA 510(k) clearance for the J.T. BAKER ALPHA-1-ANTITRYPSIN NEPHELO. Classified as Alpha-1-antitrypsin, Antigen, Antiserum, Control (product code DEM), Class II - Special Controls.

Submitted by J.T. Baker Chemical Co. (Mchenry, US). The FDA issued a Cleared decision on September 16, 1980 after a review of 56 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5130 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all J.T. Baker Chemical Co. devices

Submission Details

510(k) Number K801669 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 22, 1980
Decision Date September 16, 1980
Days to Decision 56 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
48d faster than avg
Panel avg: 104d · This submission: 56d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DEM Alpha-1-antitrypsin, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5130
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DEM Alpha-1-antitrypsin, Antigen, Antiserum, Control

All 20
Devices cleared under the same product code (DEM) and FDA review panel - the closest regulatory comparables to K801669.
ALPHA1ANTITRYPSIN FOR TECHNICON DPA-1(TM) SYSTEM
K882446 · Technicon Instruments Corp. · Jul 1988
QM300 ALPHA1-ANTITRYPSIN ANTIBODY PACK
K875281 · Kallestad Diag, A Div. of Erbamont, Inc. · Feb 1988
QM2/QM300 CONTROL B PACK
K875283 · Kallestad Diag, A Div. of Erbamont, Inc. · Feb 1988
RID SYSTEM-(ACP) TEST
K781408 · Icl Scientific · Aug 1978
LAS-R HUMAN ALPHA, ANTITRYPSIN TEST
K760916 · Hyland Therapeutic Div., Travenol Laboratories · Nov 1976